Update on lacrimal apparatus dysfunction associated with differentiated thyroid cancer after I-131 therapy.
DTC
Dry eye
I-131 therapy
NIS
NLDO
Therapies
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
23 Jun 2024
23 Jun 2024
Historique:
received:
27
02
2024
accepted:
15
06
2024
medline:
23
6
2024
pubmed:
23
6
2024
entrez:
22
6
2024
Statut:
epublish
Résumé
The most prevalent lacrimal apparatus dysfunctions associated with differentiated thyroid cancer(DTC) after I-131 therapy are dry eye and nasolacrimal duct obstruction(NLDO), leading to ocular discomfort and lower quality of life for patients. It is crucial to diagnose and manage lacrimal apparatus dysfunction associated with I-131 therapy for DTC. Therefore, this review aims to comprehensively summarize and analyze the advances in mechanisms and therapeutic options underlying lacrimal apparatus dysfunction induced by I-131 therapy for DTC. A comprehensive search of CNKI, PubMed, and Wed of Science was performed from the database to December of 2023. Key search terms were "Thyroid cancer", "I-131", "Complications", "Dry eye", "Epiphora", "Tear", "Nasolacrimal duct" and "NLDO". The research indicates that I-131 therapy for DTC causes damage to the lacrimal glands and nasolacrimal duct system, resulting in symptoms such as dry eye, epiphora, and mucoid secretions. Moreover, recent research has focused on exploring relevant risk factors of the condition and experimental and clinical treatments. However, there is some controversy regarding the mechanisms involved, whether it is due to the passive flow of I-131 in tears, active uptake of I-131 by the sodium-iodide symporter (NIS) in the lacrimal sac and nasolacrimal duct, or secondary metabolic and hormonal disturbances caused by I-131. It is crucial for early detection and preventive measures by ophthalmologists and the need for further studies to elucidate the mechanisms underlying the disease.
Identifiants
pubmed: 38909080
doi: 10.1007/s10792-024-03192-9
pii: 10.1007/s10792-024-03192-9
doi:
Substances chimiques
Iodine Radioisotopes
0
Iodine-131
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
257Subventions
Organisme : National Natural Science Foundation of China
ID : 82271094
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Vaccarella S, Dal Maso L, Laversanne M et al (2015) The impact of diagnostic changes on the rise in thyroid Cancer incidence: a Population-based study in selected high-resource countries. Thyroid 25(10):1127–1136. https://doi.org/10.1089/thy.2015.0116
doi: 10.1089/thy.2015.0116
pubmed: 26133012
Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913–2921. https://doi.org/10.1158/0008-5472.Can-14-0155
doi: 10.1158/0008-5472.Can-14-0155
pubmed: 24840647
Chiapponi C, Hartmann MJM, Decarolis B et al (2023) Differentiated thyroid cancer in adolescents: single center experience and considerations for surgical management and radioiodine treatment. J Clin Res Pediatr Endocrinol 15(3):257–263. https://doi.org/10.4274/jcrpe.galenos.2023.2023-1-16
doi: 10.4274/jcrpe.galenos.2023.2023-1-16
pubmed: 36987773
pmcid: 10448561
Riesco-Eizaguirre G, Santisteban P (2006) A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 155(4):495–512. https://doi.org/10.1530/eje.1.02257
doi: 10.1530/eje.1.02257
pubmed: 16990649
Guidelines Working Committee of Chinese Society of Clinical Oncology (2021) Guidelines of Chinese society of clinical 0ncology (CSCO) dilerentiated thyroid Cancer. Cancer Control Treat. 34(12):1164–1201. https://doi.org/10.3969/j.ssn.1674-0904.2021.12.013
doi: 10.3969/j.ssn.1674-0904.2021.12.013
Nurhidayah W, Widyasari EM, Daruwati I et al (2023) Radiosynthesis, stability, lipophilicity, and cellular uptake evaluations of [(131)I]Iodine-α-Mangostin for breast cancer diagnosis and therapy. Int J Mol Sci. https://doi.org/10.3390/ijms24108678
doi: 10.3390/ijms24108678
pubmed: 37240025
pmcid: 10218390
Glazer DI, Brown RK, Wong KK et al (2013) SPECT/CT evaluation of unusual physiologic radioiodine biodistributions: pearls and pitfalls in image interpretation. Radiograph Rev Publ Radiol Soc North Am Inc 33(2):397–418. https://doi.org/10.1148/rg.332125051
Jhiang SM, Sipos JA (2021) Na+/I- symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy. Endocrine-related Cancer 28(10):T167-t177. https://doi.org/10.1530/erc-21-0035
doi: 10.1530/erc-21-0035
pubmed: 33974556
pmcid: 8419015
Spitzweg C, Joba W, Schriever K et al (1999) Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 84(11):4178–4184. https://doi.org/10.1210/jcem.84.11.6117
doi: 10.1210/jcem.84.11.6117
pubmed: 10566669
Fard-Esfahani A, Emami-Ardekani A, Fallahi B et al (2014) Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun 35(8):808–817. https://doi.org/10.1097/mnm.0000000000000132
doi: 10.1097/mnm.0000000000000132
pubmed: 24751702
Clement SC, Peeters RP, Ronckers CM et al (2015) Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma–a systematic review. Cancer Treat Rev 41(10):925–934. https://doi.org/10.1016/j.ctrv.2015.09.001
doi: 10.1016/j.ctrv.2015.09.001
pubmed: 26421813
Zettinig G, Hanselmayer G, Fueger BJ et al (2002)long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med Mol Imaging 29 (11): 1428–1432. https://doi.org/10.1007/s00259-002-0969-0
Solans R, Bosch JA, Galofré P et Al(2001)salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 42 (5): 738–743. https://pubmed.ncbi.nlm.nih.gov/11337569/
da Fonseca FL, Yamanaka PK, Mazoti L et al (2017) Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: a prospective comparative study. Head Neck 39(12):2381–2396. https://doi.org/10.1002/hed.24895
doi: 10.1002/hed.24895
pubmed: 28945293
Fonseca FL, Lunardelli P, Matayoshi S (2012) Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma. Arq Bras Oftalmol 75(2):97–100. https://doi.org/10.1590/s0004-27492012000200005
doi: 10.1590/s0004-27492012000200005
pubmed: 22760799
Doi SA, Woodhouse NJ, Thalib L et al (2007) Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin Med Res 5(2):87–90. https://doi.org/10.3121/cmr.2007.763
doi: 10.3121/cmr.2007.763
pubmed: 17607042
pmcid: 1905932
Yartsev VD, Atkova EL, Ekaterinchev MA (2023) Topographic and anatomical features of the nasolacrimal duct obstruction due to radioiodine treatment. Int Ophthalmol 43(9):3385–3390. https://doi.org/10.1007/s10792-023-02746-7
doi: 10.1007/s10792-023-02746-7
pubmed: 37199817
Morgenstern KE, Vadysirisack DD, Zhang Z et al (2005) Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthalmic Plast Reconstr Surg 21(5):337–344. https://doi.org/10.1097/01.iop.0000179369.75569.a8
doi: 10.1097/01.iop.0000179369.75569.a8
pubmed: 16234694
Al-Qahtani KH, Al Asiri M, Tunio MA et al (2014) Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases. Clin Ophthalmol 8:2479–2484. https://doi.org/10.2147/opth.S71708
doi: 10.2147/opth.S71708
pubmed: 25525325
pmcid: 4266423
Li N, Zhang W (2023) Clinical characteristics of nasolacrimal duct obstruction after iodine therapy in differentiated thyroid cancer patients. Ear Nose Throat J. https://doi.org/10.1177/01455613231170088
doi: 10.1177/01455613231170088
pubmed: 38124322
Yartsev VD, Solodkiy VA, Fomin DK et al (2021) Clinical and demographic characteristics of tearing in patients after Radioiodine ablation for differentiated thyroid Cancer. Curr Eye Res 46(9):1320–1324. https://doi.org/10.1080/02713683.2021.1878229
doi: 10.1080/02713683.2021.1878229
pubmed: 33455422
Lee IT, Chen W, Chen Q et al (2022) Factors associated with radioactive Iodine therapy-acquired nasolacrimal duct obstruction. Endocr Pract 28(12):1210–1215. https://doi.org/10.1016/j.eprac.2022.08.006
doi: 10.1016/j.eprac.2022.08.006
pubmed: 35970353
Yartsev VD, Sheremeta MS, Trukhin AA et al (2023) Dependence of radioactive iodine-131 capture by the lacrimal ducts on the tear production level. Indian J Ophthalmol 71(5):1828–1832. https://doi.org/10.4103/ijo.Ijo_2780_22
doi: 10.4103/ijo.Ijo_2780_22
pubmed: 37203037
pmcid: 10391448
Fard-Esfahani A, Mirshekarpour H, Fallahi B et al (2007) The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. Clin Nucl Med 32(9):696–699. https://doi.org/10.1097/RLU.0b013e318124fdb6
doi: 10.1097/RLU.0b013e318124fdb6
pubmed: 17710021
Ali MJ (2023) Etiopathogenesis of primary acquired nasolacrimal duct obstruction (PANDO). Prog Retin Eye Res 96:101193. https://doi.org/10.1016/j.preteyeres.2023.101193
doi: 10.1016/j.preteyeres.2023.101193
pubmed: 37394093
Eksioglu U, Atilgan HI, Yakin M et al (2019) Antioxidant effects of vitamin D on lacrimal glands against high dose radioiodine-associated damage in an animal model. Cutan Ocul Toxicol 38(1):18–24. https://doi.org/10.1080/15569527.2018.1498507
doi: 10.1080/15569527.2018.1498507
pubmed: 30003810
Koca G, Singar E, Akbulut A et al (2021) The effect of resveratrol on radioiodine therapy-associated lacrimal gland damage. Curr Eye Res 46(3):398–407. https://doi.org/10.1080/02713683.2020.1803920
doi: 10.1080/02713683.2020.1803920
pubmed: 32730712
Fedorov AA, Atkova EL, Yartsev VD (2020) Secondary acquired nasolacrimal duct obstruction as a specific complication of treatment with radioactive Iodine (Morphological Study). Ophthalmic Plast Reconstr Surg 36(3):250–253. https://doi.org/10.1097/iop.0000000000001521
doi: 10.1097/iop.0000000000001521
pubmed: 31743278
Usmani S, Jain A, Al-Riyami K et al (2023) Accumulation of 131 Iodine in the nasolacrimal sac/duct after radioiodine therapy for papillary thyroid cancer. J Pak Med Assoc 73(3): 713–714. https://doi.org/10.47391/jpma.23-22
Lee IT, Grice JV, Ji X et al (2024) A pilot nonrandomized controlled trial examining the use of artificial tears on the radioactivity of tears after radioactive Iodine treatment for thyroid cancer. Thyroid 34(1):82–87. https://doi.org/10.1089/thy.2023.0338
doi: 10.1089/thy.2023.0338
pubmed: 37917111
Bakheet SM, Hammami MM, Hemidan A et al (1998) Radioiodine secretion in tears. J Nucl Med 39(8):1452–1454
pubmed: 9708527
Zettinig G, Karanikas G, Hanselmayer G et al (2000) Radioactive contamination of contact lenses during radioiodine therapy. Nucl Med Commun 21(10):955–957. https://doi.org/10.1097/00006231-200010000-00010
doi: 10.1097/00006231-200010000-00010
pubmed: 11130337
Ketchum CJ, Rajendrakumar GV, Maloney PC (2004) Characterization of the adenosinetriphosphatase and transport activities of purified cystic fibrosis transmembrane conductance regulator. Biochemistry 43(4):1045–1053. https://doi.org/10.1021/bi035382a
doi: 10.1021/bi035382a
pubmed: 14744150
Berman M, Hoff E, Barandes M et al (1968) Iodine kinetics in man–a model. J Clin Endocrinol Metab 28(1):1–14. https://doi.org/10.1210/jcem-28-1-1
doi: 10.1210/jcem-28-1-1
pubmed: 5694134
Singh S, Hammer CM, Paulsen F (2023) Urea and ocular surface: synthesis, secretion and its role in tear film homeostasis. Ocul Surf 27:41–47. https://doi.org/10.1016/j.jtos.2022.11.003
doi: 10.1016/j.jtos.2022.11.003
pubmed: 36375795
Zhan X, Li J, Guo Y et al (2021) Mass spectrometry analysis of human tear fluid biomarkers specific for ocular and systemic diseases in the context of 3P medicine. EPMA J 12(4):449–475. https://doi.org/10.1007/s13167-021-00265-y
doi: 10.1007/s13167-021-00265-y
pubmed: 34876936
pmcid: 8639411
Chudgar AV, Shah JC (2017) Pictorial Review of False-Positive Results on Radioiodine scintigrams of patients with differentiated thyroid Cancer. Radiogr Rev Publ Radiol Soc North Am Inc 37(1): 298–315. https://doi.org/10.1148/rg.2017160074
Kiratli PO, Kara PP, Ergün EL et al (2004) Metastatic insular thyroid carcinoma: visualized on Tc-99m pertechnetate, Tc-99m MDP and iodine-131 scintigraphy; a review of the literature for other radionuclide agents. Ann Nucl Med 18(5):443–446. https://doi.org/10.1007/bf02984488
doi: 10.1007/bf02984488
pubmed: 15462407
Ozcan Kara P, Gunay EC, Erdogan A (2014) Radioiodine Contamination artifacts and unusual patterns of Accumulation in whole-body I-131 imaging: a Case Series. Int J Endocrinol Metabolism 12(1):e9329. https://doi.org/10.5812/ijem.9329
doi: 10.5812/ijem.9329
Levy O, De la Vieja A, Ginter CS et al (1998) N-linked glycosylation of the thyroid Na+/I- symporter (NIS). Implications for its secondary structure model. J Biol Chem 273(35): 22657–22663. https://doi.org/10.1074/jbc.273.35.22657
Ali MJ, Vyakaranam AR, Rao JE et al (2017) Iodine-131 therapy and lacrimal drainage system toxicity: nasal localization studies using whole body nuclear scintigraphy and SPECT-CT. Ophthalmic Plast Reconstr Surg 33(1):13–16. https://doi.org/10.1097/iop.0000000000000603
doi: 10.1097/iop.0000000000000603
pubmed: 26669292
Sakahara H, Yamashita S, Suzuki K et al (2007) Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer. Ann Nucl Med 21(9):525–527. https://doi.org/10.1007/s12149-007-0056-5
doi: 10.1007/s12149-007-0056-5
pubmed: 18030585
Yuoness S, Rachinsky I, Driedger AA et al (2011) Differentiated thyroid cancer with epiphora: detection of nasolacrimal duct obstruction on I-131 SPECT/CT. Clin Nuclear Med 36(12):1149–1152. https://doi.org/10.1097/RLU.0b013e3182336016
doi: 10.1097/RLU.0b013e3182336016
Markitziu A, Lustmann J, Uzieli B et al (1993) Salivary and lacrimal gland involvement in a patient who had undergone a thyroidectomy and was treated with radioiodine for thyroid cancer. Oral Surg Oral Med Oral Pathol 75(3):318–322. https://doi.org/10.1016/0030-4220(93)90144-s
doi: 10.1016/0030-4220(93)90144-s
pubmed: 8469542
Koca G, Yalniz-Akkaya Z, Gültekin SS et al (2013) Radioprotective effect of montelukast sodium in rat lacrimal glands after radioiodine treatment. Rev Esp Med Nucl Imagen Mol 32(5):294–300. https://doi.org/10.1016/j.remn.2013.01.006
doi: 10.1016/j.remn.2013.01.006
pubmed: 23499122
Acar DE, Acar U, Yumusak N et al (2014) Reducing the histopathological changes of radioiodine to the lacrimal glands by a popular anti-oxidant: lycopene. Curr Eye Res 39(7):659–665. https://doi.org/10.3109/02713683.2013.867354
doi: 10.3109/02713683.2013.867354
pubmed: 24871924
Acar U, Atilgan HI, Acar DE et al (2013) The effect of short-term vitamin E against radioiodine-induced early lacrimal gland damage. Ann Nucl Med 27(10):886–891. https://doi.org/10.1007/s12149-013-0763-z
doi: 10.1007/s12149-013-0763-z
pubmed: 23979966
Ornek F, Acar DE, Acar U et al (2017) Short- and long-term effects of zinc treatment on lacrimal gland histopathology and tear functions tests in radioiodine-administered rats. Arq Bras Oftalmol 80(1):35–40. https://doi.org/10.5935/0004-2749.20170010
doi: 10.5935/0004-2749.20170010
pubmed: 28380100
Yakin M, Eksioglu U, Sadic M et al (2017) Coenzyme Q10 for the protection of lacrimal gland against high-dose radioiodine therapy-associated oxidative damage: histopathologic and tissue cytokine level assessments in an animal model. Curr Eye Res 42(12):1590–1596. https://doi.org/10.1080/02713683.2017.1362006
doi: 10.1080/02713683.2017.1362006
pubmed: 28937867
Atilgan HI, Akbulut A, Yazihan N et al (2023) The cytokines-Directed roles of spirulina for radioprotection of lacrimal gland. Ocular Immunol Inflamm 31(2):271–276. https://doi.org/10.1080/09273948.2022.2026409
doi: 10.1080/09273948.2022.2026409
Ravera S, Reyna-Neyra A, Ferrandino G et al (2017) The Sodium/Iodide Symporter (NIS): molecular physiology and preclinical and clinical applications. Annu Rev Physiol 79:261–289. https://doi.org/10.1146/annurev-physiol-022516-034125
doi: 10.1146/annurev-physiol-022516-034125
pubmed: 28192058
pmcid: 5739519
Burns JA, Morgenstern KE, Cahill KV et al (2004) Nasolacrimal obstruction secondary to I(131) therapy. Ophthalmic Plast Reconstr Surg 20(2):126–129. https://doi.org/10.1097/01.iop.0000117340.41849.81
doi: 10.1097/01.iop.0000117340.41849.81
pubmed: 15083081
Lee IT, Grice JV, Ji X et al (2023) A pilot nonrandomized controlled trial examining the use of artificial tears on the radioactivity of tears after radioactive Iodine treatment for thyroid cancer. Thyroid 34(1):82–87. https://doi.org/10.1089/thy.2023.0338
doi: 10.1089/thy.2023.0338
pubmed: 37917111
Jung SK, Kim YC, Cho WK et al (2015) Surgical outcomes of endoscopic dacryocystorhinostomy: analysis of 1083 consecutive cases. Canadian journal of ophthalmology. J Canadien d’ophtalmologie 50(6): 466–470. https://doi.org/10.1016/j.jcjo.2015.08.007
Sweeney AR, Davis GE, Chang SH et al (2018) Outcomes of endoscopic dacryocystorhinostomy in secondary acquired nasolacrimal duct obstruction: a case-control study. Ophthalmic Plast Reconstr Surg 34(1):20–25. https://doi.org/10.1097/iop.0000000000000841
doi: 10.1097/iop.0000000000000841
pubmed: 27997463
Panda BB, Nayak B, Mohapatra S et al (2023) Success and complications of endoscopic laser dacryocystorhinostomy vs. external dacryocystorhinostomy: a systematic review and meta-analysis. Indian J Ophthalmol 71(10):3290–3298. https://doi.org/10.4103/ijo.Ijo_3334_22
doi: 10.4103/ijo.Ijo_3334_22
pubmed: 37787224
pmcid: 10683697
Rajabi MT, Shahraki K, Nozare A et al (2022) External versus endoscopic dacryocystorhinostomy for primary acquired nasolacrimal duct obstruction. Middle East Afr J Ophthalmol 29(1):1–6. https://doi.org/10.4103/meajo.meajo_238_21
doi: 10.4103/meajo.meajo_238_21
pubmed: 36685339
pmcid: 9846961
Bakri K, Jones NS, Downes R et al (2003) Intraoperative fluorouracil in endonasal laser dacryocystorhinostomy. Arch Otolaryngol Head Neck Surg 129(2):233–235. https://doi.org/10.1001/archotol.129.2.233
doi: 10.1001/archotol.129.2.233
pubmed: 12578455
Ji QS, Zhong JX, Tu YH et al (2012) New mucosal flap modification for endonasal endoscopic dacryocystorhinostomy in asians. Int J Ophthalmol 5(6):704–707. https://doi.org/10.3980/j.issn.2222-3959.2012.06.10
doi: 10.3980/j.issn.2222-3959.2012.06.10
pubmed: 23275904
pmcid: 3530812
Cheng SM, Feng YF, Xu L et al (2013) Efficacy of mitomycin C in endoscopic dacryocystorhinostomy: a systematic review and meta-analysis. PLoS ONE 8(5):e62737. https://doi.org/10.1371/journal.pone.0062737
doi: 10.1371/journal.pone.0062737
pubmed: 23675423
pmcid: 3652813
Chan DM, Golubev I, Shipchandler TZ et al (2014) Improving outcomes by combining septoplasty with primary external dacryocystorhinostomy. Am J Otolaryngol 35(3):309–312. https://doi.org/10.1016/j.amjoto.2014.02.006
doi: 10.1016/j.amjoto.2014.02.006
pubmed: 24629586
Okuyucu S, Gorur H, Oksuz H et al (2015) Endoscopic dacryocystorhinostomy with silicone, polypropylene, and T-tube stents; randomized controlled trial of efficacy and safety. Am J Rhinol Allergy 29(1):63–68. https://doi.org/10.2500/ajra.2015.29.4119
doi: 10.2500/ajra.2015.29.4119
pubmed: 25590323
Li EY, Wong ES, Wong AC et al (2017) Primary vs secondary endoscopic dacryocystorhinostomy for Acute Dacryocystitis with lacrimal sac abscess formation: a randomized clinical trial. JAMA Ophthalmol 135(12):1361–1366. https://doi.org/10.1001/jamaophthalmol.2017.4798
doi: 10.1001/jamaophthalmol.2017.4798
pubmed: 29121183
pmcid: 6583760
Li J, Wang J, Sun C (2023) Efficacy of hyaluronic acid in endoscopic dacryocystorhinostomy: a systematic review and Meta-analysis. Am J Rhinol Allergy 37(1):102–109. https://doi.org/10.1177/19458924221126356
doi: 10.1177/19458924221126356
pubmed: 36113103